0.25 mg RPC1063 ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	9
96	Crohn disease	1
97	Ulcerative colitis	23

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-002714-40-HR (EUCTR)	17/10/2014	05/11/2014	A CLINICAL STUDY TO EVALUATE IN A BLINDED AND SCIENTIFIC WAY THE EFFICACY AND SAFETY OF THE NEW MEDI ...	A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, D ...	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 17.1;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25 mg RPC1063 INN or Proposed INN: RPC1063 Product Name: 0.5 mg RPC1063 INN or Proposed ...	Receptos, Inc.	NULL	Not Recruiting	Female: yes Male: yes	1410	Phase 2;Phase 3	Serbia;United States;Belarus;Slovakia;Slovenia;Greece;Spain;Ukraine;Russian Federation;Italy;United ...
2	EUCTR2012-002714-40-SK (EUCTR)	02/06/2014	12/03/2014	A CLINICAL STUDY TO EVALUATE IN A BLINDED AND SCIENTIFIC WAY THE EFFICACY AND SAFETY OF THE NEW MEDI ...	A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, D ...	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 18.1;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25 mg RPC1063 INN or Proposed INN: RPC1063 Product Name: 0.5 mg RPC1063 INN or Proposed ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting	Female: yes Male: yes	1578	Phase 2;Phase 3	Serbia;United States;Belarus;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;United Kingdom;H ...
3	EUCTR2012-002714-40-GB (EUCTR)	29/05/2014	28/02/2014	A CLINICAL STUDY TO EVALUATE IN A BLINDED AND SCIENTIFIC WAY THE EFFICACY AND SAFETY OF THE NEW MEDI ...	A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, D ...	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 18.1;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25 mg RPC1063 INN or Proposed INN: RPC1063 Product Name: 0.5 mg RPC1063 INN or Proposed ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting	Female: yes Male: yes	1265	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	Serbia;United States;Belarus;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;United Kingdom;H ...
4	EUCTR2012-002714-40-ES (EUCTR)	02/08/2013	09/04/2013	A CLINICAL STUDY TO EVALUATE IN A BLINDED AND SCIENTIFIC WAY THE EFFICACY AND SAFETY OF THE NEW MEDI ...	A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, D ...	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 14.1;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25 mg RPC1063 INN or Proposed INN: RPC1063 Product Name: 0.5 mg RPC1063 INN or Proposed ...	Receptos, Inc.	NULL	Not Recruiting	Female: yes Male: yes	1280	Phase 2;Phase 3	Serbia;United States;Slovakia;Greece;Spain;Ukraine;Israel;Russian Federation;Italy;United Kingdom;Hu ...
5	EUCTR2012-002714-40-GR (EUCTR)	10/07/2013	17/05/2013	A CLINICAL STUDY TO EVALUATE IN A BLINDED AND SCIENTIFIC WAY THE EFFICACY AND SAFETY OF THE NEW MEDI ...	A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, D ...	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 16.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25 mg RPC1063 INN or Proposed INN: RPC1063 Product Name: 0.5 mg RPC1063 INN or Proposed ...	Receptos, Inc.	NULL	Not Recruiting	Female: yes Male: yes	1280	Phase 2;Phase 3	Serbia;United States;Slovakia;Greece;Spain;Ukraine;Israel;Russian Federation;Italy;United Kingdom;Hu ...
6	EUCTR2012-002714-40-HU (EUCTR)	10/06/2013	02/05/2013	A CLINICAL STUDY TO EVALUATE IN A BLINDED AND SCIENTIFIC WAY THE EFFICACY AND SAFETY OF THE NEW MEDI ...	A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, D ...	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 19.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25 mg RPC1063 INN or Proposed INN: Ozanimod Product Name: 0.5 mg RPC1063 INN or Propose ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting	Female: yes Male: yes	1578	Phase 2;Phase 3	Serbia;United States;Belarus;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;United Kingdom;H ...
7	EUCTR2012-002714-40-BG (EUCTR)	17/05/2013	08/05/2013	A CLINICAL STUDY TO EVALUATE IN A BLINDED AND SCIENTIFIC WAY THE EFFICACY AND SAFETY OF THE NEW MEDI ...	A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, D ...	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 19.1;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25 mg RPC1063 INN or Proposed INN: Ozanimod Product Name: 0.5 mg RPC1063 INN or Propose ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting	Female: yes Male: yes	1578	Phase 2;Phase 3	Serbia;United States;Belarus;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;United Kingdom;H ...
8	EUCTR2012-002714-40-IT (EUCTR)	09/05/2013	08/03/2013	A CLINICAL STUDY TO EVALUATE IN A BLINDED AND SCIENTIFIC WAY THE EFFICACY AND SAFETY OF THE NEW MEDI ...	A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, D ...	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 14.1;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25 mg RPC1063 INN or Proposed INN: RPC1063 Product Name: 0.5 mg RPC1063 INN or Proposed ...	Receptos, Inc.	NULL	Not Recruiting	Female: yes Male: yes	1280	Phase 2;Phase 3	Serbia;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;United Kingdom;Italy;Hu ...
9	EUCTR2012-002714-40-BE (EUCTR)	29/04/2013	14/03/2013	A CLINICAL STUDY TO EVALUATE IN A BLINDED AND SCIENTIFIC WAY THE EFFICACY AND SAFETY OF THE NEW MEDI ...	A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, D ...	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 18.1;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25 mg RPC1063 INN or Proposed INN: Ozanimod Product Name: 0.5 mg RPC1063 INN or Propose ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting	Female: yes Male: yes	1578	Phase 2;Phase 3	Serbia;United States;Belarus;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;United Ki ...

First Previous1Next Last

96. Crohn disease

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-002025-19-PL (EUCTR)	28/01/2016	21/12/2015	An open-label study to assess improvement in patients with Moderate to Severe Crohn’s Disease taking ...	A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Impro ...	Moderately to Severely Active Crohn's Disease MedDRA version: 20.1;Level: LLT;Classification code 10 ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl (CIS II), a wholly owned subsidiary of Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;Hungary;Canada;Poland;Ukraine

First Previous1Next Last

97. Ulcerative colitis

Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

diseases per page:

Showing 1 to 10 of 23 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-001600-64-AT (EUCTR)	25/07/2018	17/04/2018	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Not Recruiting	Female: yes Male: yes	1200	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Australia ...
2	EUCTR2015-000319-41-GR (EUCTR)	23/07/2018	18/04/2018	The purpose of this study is to determine whether RPC1063 is safe and effective in the treatment of ...	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induct ...	ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting	Female: yes Male: yes	900	Phase 3	United States;Belarus;Slovakia;Greece;Spain;Ukraine;Israel;Russian Federation;Italy;France;Australia ...
3	EUCTR2015-001600-64-GR (EUCTR)	23/07/2018	19/04/2018	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	1200	Phase 3	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Australia ...
4	EUCTR2015-001600-64-ES (EUCTR)	12/07/2018	21/05/2018	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Not Recruiting	Female: yes Male: yes	1200	Phase 3	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Australia ...
5	EUCTR2015-001600-64-LV (EUCTR)	22/06/2018	13/04/2018	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	1200	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Bulgaria;Croatia;Poland;Belgium;Argentina;Canada;Hungary;Czech Republic;United Kingdom;Austria;Korea ...
6	EUCTR2015-001600-64-HR (EUCTR)	19/01/2017	05/06/2017	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	1350	Phase 3	United States;Belarus;Serbia;Slovakia;Greece;Spain;Ukraine;Israel;Russian Federation;Italy;Australia ...
7	EUCTR2015-001600-64-BG (EUCTR)	13/10/2016	01/10/2015	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Trade Name: ZEPOSIA® (ozanimod) Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	1350	Phase 3	United States;Belarus;Serbia;Slovakia;Greece;Spain;Ukraine;Israel;Russian Federation;Italy;Australia ...
8	EUCTR2015-001600-64-NL (EUCTR)	28/04/2016	13/10/2015	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Trade Name: ZEPOSIA® (ozanimod) Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	1200	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;Australia ...
9	EUCTR2015-001600-64-IT (EUCTR)	05/01/2016	28/01/2021	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 asTherapy for Moderate to Severe ...	Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod Other descriptive nam ...	CELGENE INTERNATIONAL II SàRL	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	1350	Phase 3	Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Chile;Colombia;Italy;A ...
10	EUCTR2015-001600-64-BE (EUCTR)	30/11/2015	01/03/2016	The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the tre ...	A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe ...	Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ...	Trade Name: ZEPOSIA® (ozanimod) Product Name: 0.25 mg RPC1063 Product Code: RPC1063 INN or Proposed INN ...	Celgene International II Sàrl	NULL	Authorised-recruitment may be ongoing or finished	Female: yes Male: yes	1350	Phase 3	Serbia;Belarus;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;Australia ...

First Previous1 2 3Next Last